RCKT logo

Rocket Pharmaceuticals, Inc. Common Stock


RCKT: Rocket Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.


Show RCKT Financials

Consumer Interest
SEC Filings

Recent trades of RCKT by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quarterly net insider trading by RCKT's directors and management

Government lobbying spending instances

  • $10,000 Jul 19, 2022 Issue: Health Issues
  • $10,000 Apr 20, 2022 Issue: Health Issues
  • $10,000 Jan 20, 2022 Issue: Health Issues
  • $10,000 Nov 19, 2021 Issue: Health Issues
  • $10,000 Jul 19, 2021 Issue: Health Issues
  • $30,000 Oct 20, 2020 Issue: Immigration
  • $20,000 Jul 17, 2020 Issue: Immigration
  • $20,000 Apr 13, 2020 Issue: Immigration
  • $40,000 Jan 15, 2020 Issue: Immigration
U.S. Patents

New patents grants

  • Patent Title: Gene therapy vectors for treatment of danon disease Jul. 07, 2020
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of RCKT in WallStreetBets Daily Discussion


Recent insights relating to RCKT

CNBC Recommendations

Recent picks made for RCKT stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in RCKT

Corporate Flights

Flights by private jets registered to RCKT